v3.25.2
Goodwill and Intangible Assets
12 Months Ended
Jul. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets
Note 6. Goodwill and Intangible Assets
Goodwill
The Company allocates goodwill to reporting units within its Mobile Solutions, Industrial Solutions and Life Sciences segments. There were no dispositions or impairment charges recorded during the years ended July 31, 2025, 2024 and 2023. Goodwill is assessed for impairment annually during the third quarter of the fiscal year, or more frequently if events or changes in circumstances indicate the asset may be impaired. The Company performed its annual impairment assessment during the third quarter of fiscal 2025 and did not record any impairment as a result of this assessment.
Goodwill by reportable segment was as follows (in millions):
Mobile
Solutions
Segment
Industrial
Solutions
Segment
Life Sciences SegmentTotal
Goodwill
Balance as of July 31, 2023$25.5 $289.1 $166.5 $481.1 
Goodwill acquired— 1.9 — 1.9 
Purchase price adjustments— — (1.1)(1.1)
Foreign exchange translation(0.1)(1.1)(2.3)(3.5)
 Balance as of July 31, 2024$25.4 $289.9 $163.1 $478.4 
Goodwill acquired— 3.2 — 3.2 
Foreign exchange translation— 5.1 6.9 12.0 
Balance as of July 31, 2025$25.4 $298.2 $170.0 $493.6 
Intangible Assets
Intangible asset classes were as follows (in millions):
Year Ended July 31, 2025
Weighted Amortizable Life (in Years)Gross Carrying AmountAccumulated AmortizationNet
Customer relationships8.5$74.7 $(43.7)$31.0 
Trademarks6.73.8 (2.0)1.8 
Technology and patents
16.682.9 (19.1)63.8 
Non-compete agreements2.92.5 (1.7)0.8 
Total intangible assets$163.9 $(66.5)$97.4 
Year Ended July 31, 2024
Weighted Amortizable Life (in Years)Gross Carrying AmountAccumulated AmortizationNet
Customer relationships9.4$77.4 $(39.9)$37.5 
Trademarks8.114.2 (3.8)10.4 
Technology and patents
16.7142.4 (20.4)122.0 
Non-compete agreements2.73.9 (1.9)2.0 
Total intangible assets$237.9 $(66.0)$171.9 
In the third quarter of fiscal 2025, the Company identified a triggering event related to certain asset groups and performed a valuation of certain long-lived intangible assets in accordance with ASC 360, Impairment and Disposal of Long-Lived Assets. The Company used a discounted cash flow analysis to estimate the fair value of each long-lived asset group. Estimates and assumptions are utilized in the valuations, including discounted projected cash flows, earnings before interest, taxes, depreciation and amortization margins, terminal value growth rates, revenue growth rates, discount rates and the determination of comparable publicly traded companies. As a result of the valuation, the Company recorded $62.0 million of impairment expense related to intangible assets in the Company’s bioprocessing businesses within the Life Sciences segment, including $53.1 million of impairment expense related to technology and patents, $7.7 million of impairment expense related to trademarks, $1.0 million of impairment expense related to customer relationships and $0.2 of impairment expense related to non-compete agreements. The impairment expense was included in loss on impairment of intangible assets in the Consolidated Statements of Earnings. Of the impairment expense, $46.6 million was related to Univercells Technologies, reflecting lower-than-anticipated bioprocessing capital spending, particularly for early-stage assets, while drug development timelines are longer than previously anticipated. The remaining $15.4 million of impairment expense was related to Solaris as market demand for industrial bioreactors had significantly declined.
The Company recognized a foreign currency translation gain of $3.0 million in fiscal 2025 and a translation loss of $1.4 million in fiscal 2024.
Intangible asset amortization expense was $13.9 million, $15.7 million and $11.4 million for the fiscal 2025, 2024 and 2023, respectively and is included in operating expenses in the Consolidated Statements of Earnings. Amortization expense relating to existing intangible assets as of July 31, 2025 was as follows (in millions):
2026$9.4 
20279.0 
20288.6 
20297.5 
20307.1 
Thereafter55.8 
Total amortization expense$97.4